citalopram has been researched along with Alcohol Abuse in 54 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The drugs relieve depressive disorders: fluvoxamine by the 7th day of treatment, sertraline, paroxetine, citalopram by the 14th day, fluoxetine by the 30th day of therapy." | 9.41 | [Fluvoxamine in the treatment of depressive disorders in alcohol dependence: results of randomized open-label comparative study]. ( Komarov, SD; Severtsev, VV; Vdovin, AS; Vinnikova, MA, 2021) |
| "The effect of citalopram and placebo in the treatment of alcoholism was studied in a sample of 62 patients with a follow-up period of four months." | 9.08 | Citalopram in the treatment of alcoholism: a double-blind placebo-controlled study. ( Hakola, HP; Kauhanen, J; Ryynänen, OP; Salaspuro, M; Tiihonen, J, 1996) |
| "The drugs relieve depressive disorders: fluvoxamine by the 7th day of treatment, sertraline, paroxetine, citalopram by the 14th day, fluoxetine by the 30th day of therapy." | 5.41 | [Fluvoxamine in the treatment of depressive disorders in alcohol dependence: results of randomized open-label comparative study]. ( Komarov, SD; Severtsev, VV; Vdovin, AS; Vinnikova, MA, 2021) |
| "Two hundred and sixty-five patients meeting criteria for a DSM-IV diagnosis of alcohol abuse or dependence were randomly assigned to receive placebo or citalopram 20 mg per day for the first week, followed by 40 mg per day from weeks 2 through 12." | 5.20 | Poorer Drinking Outcomes with Citalopram Treatment for Alcohol Dependence: A Randomized, Double-Blind, Placebo-Controlled Trial. ( Charney, DA; Gill, KJ; Heath, LM; Palacios-Boix, J; Zikos, E, 2015) |
| "The effect of citalopram and placebo in the treatment of alcoholism was studied in a sample of 62 patients with a follow-up period of four months." | 5.08 | Citalopram in the treatment of alcoholism: a double-blind placebo-controlled study. ( Hakola, HP; Kauhanen, J; Ryynänen, OP; Salaspuro, M; Tiihonen, J, 1996) |
| " In the first case, the drugs venlafaxine, amiodarone and domperidone may have contributed to QT interval prolongation in a patient with hypokalemia and hypomagnesaemia." | 3.76 | Multifactorial QT interval prolongation. ( Baranchuk, A; Digby, G; Machaalany, J; Malik, P; Methot, M; Redfearn, D; Simpson, CS, 2010) |
| "Depression commonly co-occurs with alcohol use disorders but predictors of depression treatment outcome in patients with both conditions are not well established." | 2.80 | Depression outcome in alcohol dependent patients: an evaluation of the role of independent and substance-induced depression and other predictors. ( Adamson, SJ; Boden, JM; Douglas Sellman, J; Foulds, JA; Joyce, PR; Mulder, RT, 2015) |
| "In the new era of naltrexone for alcohol dependence, it is notable that only 1 study to date has examined the efficacy of antidepressant medication prescribed concurrently with naltrexone." | 2.80 | A randomized trial of combined citalopram and naltrexone for nonabstinent outpatients with co-occurring alcohol dependence and major depression. ( Adamson, SJ; Berks, J; Cape, G; Deering, D; Dunn, A; Foulds, JA; Frampton, CM; Nixon, L; Sellman, JD, 2015) |
| "Thirty-five subjects with major depressive disorder and alcohol dependence were recruited and randomly assigned into 17 aripiprazole + escitalopram and 18 escitalopram only groups." | 2.78 | Adjunctive aripiprazole therapy with escitalopram in patients with co-morbid major depressive disorder and alcohol dependence: clinical and neuroimaging evidence. ( Choi, JE; Han, DH; Kim, SM; Min, KJ; Renshaw, PF, 2013) |
| "Memantine was at least as effective with regard to drinking as escitalopram." | 2.73 | Treatment of alcohol dependence in patients with co-morbid major depressive disorder--predictors for the outcomes with memantine and escitalopram medication. ( Alho, H; Lahti, J; Lönnqvist, J; Muhonen, LH; Sinclair, D, 2008) |
| "Three cases of patients presenting a substance use disorder with comorbid major depression episodes are presented, who were treated with a reboxetine/escitalopram combination and who showed a rapid response of their depressive syndrome." | 2.71 | Escitalopram/reboxetine combination in depressed patients with substance use disorder. ( Camarasa, X; Duboc, A; Khazaal, Y; Lopez-Martinez, E; Zullino, DF, 2005) |
| "Alcohol intake was monitored daily and alcohol dependence (ADS) and problems (MAST) were assessed at intake and post-treatment." | 2.68 | Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems. ( Bremner, KE; Lanctôt, KL; Naranjo, CA, 1995) |
| "Citalopram is a selective serotonin re-uptake inhibitor that has demonstrated antidepressant efficacy in numerous controlled clinical trials." | 2.41 | Citalopram: a comprehensive review. ( Pollock, BG, 2001) |
| "Adult men with a diagnosis of alcohol dependence (n = 18) were recruited from outpatient treatment units for alcoholism." | 1.39 | Childhood maltreatment affects the serotonergic system in male alcohol-dependent individuals. ( Balldin, J; Berggren, U; Berglund, KJ; Fahlke, C; Gerdner, A, 2013) |
| "Alcohol dependence has been associated with reduced function of serotonin, dopamine as well as noradrenaline activities in several neuroendocrine studies." | 1.38 | Neuroendocrine assessment of serotonergic, dopaminergic, and noradrenergic functions in alcohol-dependent individuals. ( Balldin, J; Berggren, U; Berglund, KJ; Blennow, K; Engel, JA; Fahlke, C; Zetterberg, H, 2012) |
| "However, as his PTSD symptoms remitted, so did his tic symptoms." | 1.35 | Attenuation of apparent new-onset ocular tics with successful treatment of PTSD. ( Drouillard, GJ; Gallagher, MB; Hayes, PC; Weber, CL, 2009) |
| "Citalopram was retested 18 weeks after the first treatment during 1 week, with continuous access to ethanol; 10 mg/kg had no effect and 40 mg/kg decreased ethanol intake at day 1, reaching a minimum in day 3." | 1.30 | Citalopram as an inhibitor of voluntary ethanol intake in the male rat. ( Hedlund, L; Wahlström, G, 1998) |
| "Buspirone was without important effects on the high alcohol preferring rats." | 1.29 | Effects of various serotonergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference. ( Meert, TF, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (9.26) | 18.7374 |
| 1990's | 13 (24.07) | 18.2507 |
| 2000's | 19 (35.19) | 29.6817 |
| 2010's | 16 (29.63) | 24.3611 |
| 2020's | 1 (1.85) | 2.80 |
| Authors | Studies |
|---|---|
| Vinnikova, MA | 1 |
| Severtsev, VV | 1 |
| Komarov, SD | 1 |
| Vdovin, AS | 1 |
| Anthenelli, RM | 2 |
| Heffner, JL | 2 |
| Blom, TJ | 2 |
| Daniel, BE | 1 |
| McKenna, BS | 1 |
| Wand, GS | 1 |
| Zorick, T | 1 |
| Okita, K | 1 |
| Mandelkern, MA | 1 |
| London, ED | 1 |
| Brody, AL | 1 |
| Prakash, S | 1 |
| Mandal, P | 1 |
| Kärkkäinen, O | 1 |
| Laukkanen, V | 1 |
| Haukijärvi, T | 4 |
| Kautiainen, H | 1 |
| Tiihonen, J | 6 |
| Storvik, M | 4 |
| Foulds, JA | 3 |
| Douglas Sellman, J | 1 |
| Adamson, SJ | 3 |
| Boden, JM | 2 |
| Mulder, RT | 2 |
| Joyce, PR | 1 |
| Sellman, JD | 2 |
| Frampton, CM | 1 |
| Deering, D | 1 |
| Dunn, A | 1 |
| Berks, J | 1 |
| Nixon, L | 1 |
| Cape, G | 1 |
| Charney, DA | 1 |
| Heath, LM | 1 |
| Zikos, E | 1 |
| Palacios-Boix, J | 1 |
| Gill, KJ | 1 |
| Newton-Howes, G | 1 |
| Muhonen, LH | 4 |
| Lahti, J | 3 |
| Sinclair, D | 1 |
| Lönnqvist, J | 4 |
| Alho, H | 4 |
| Husain, MM | 1 |
| Rush, AJ | 1 |
| Wisniewski, SR | 1 |
| McClintock, SM | 1 |
| Fava, M | 2 |
| Nierenberg, AA | 1 |
| Davis, L | 1 |
| Balasubramani, GK | 1 |
| Young, E | 1 |
| Albala, AA | 1 |
| Trivedi, MH | 1 |
| Hayes, PC | 1 |
| Weber, CL | 1 |
| Gallagher, MB | 1 |
| Drouillard, GJ | 1 |
| Tran, GQ | 1 |
| Johnson, CS | 1 |
| Barrett, SW | 1 |
| Thompson, RD | 1 |
| Digby, G | 1 |
| Machaalany, J | 1 |
| Malik, P | 1 |
| Methot, M | 1 |
| Simpson, CS | 1 |
| Redfearn, D | 1 |
| Baranchuk, A | 1 |
| Haukka, J | 1 |
| Saarikoski, ST | 1 |
| Fahlke, C | 3 |
| Berggren, U | 5 |
| Berglund, KJ | 2 |
| Zetterberg, H | 1 |
| Blennow, K | 1 |
| Engel, JA | 1 |
| Balldin, J | 5 |
| Sivolap, IuP | 1 |
| Witte, J | 1 |
| Bentley, K | 1 |
| Evins, AE | 1 |
| Clain, AJ | 1 |
| Baer, L | 1 |
| Pedrelli, P | 1 |
| Mischoulon, D | 1 |
| Han, DH | 1 |
| Kim, SM | 1 |
| Choi, JE | 1 |
| Min, KJ | 1 |
| Renshaw, PF | 1 |
| Gerdner, A | 1 |
| Gotjen, D | 1 |
| Szabo, Z | 1 |
| Lee, S | 1 |
| Wand, G | 1 |
| Camarasa, X | 1 |
| Lopez-Martinez, E | 1 |
| Duboc, A | 1 |
| Khazaal, Y | 1 |
| Zullino, DF | 1 |
| Ose, BL | 1 |
| Pandurangi, AK | 1 |
| Gorman, JM | 1 |
| Tupala, E | 4 |
| Lindberg, N | 1 |
| Tani, P | 1 |
| Takala, P | 1 |
| Sailas, E | 1 |
| Putkonen, H | 1 |
| Eronen, M | 1 |
| Virkkunen, M | 1 |
| Wong, WM | 1 |
| Hasemann, S | 1 |
| Schwarz, M | 1 |
| Zill, P | 1 |
| Koller, G | 1 |
| Soyka, M | 1 |
| Preuss, UW | 1 |
| Juva, K | 1 |
| Stella, L | 1 |
| Addolorato, G | 1 |
| Rinaldi, B | 1 |
| Capuano, A | 1 |
| Berrino, L | 1 |
| Rossi, F | 1 |
| Maione, S | 1 |
| Naranjo, CA | 11 |
| Bremner, KE | 5 |
| Engel, J | 2 |
| Eriksson, M | 3 |
| Hård, E | 2 |
| Söderpalm, B | 1 |
| Lanctôt, KL | 2 |
| Meert, TF | 1 |
| Ryynänen, OP | 1 |
| Kauhanen, J | 1 |
| Hakola, HP | 1 |
| Salaspuro, M | 1 |
| Bazoon, M | 1 |
| Turksen, IB | 1 |
| Druse, MJ | 1 |
| Tajuddin, NF | 1 |
| Ricken, JD | 1 |
| Hedlund, L | 1 |
| Wahlström, G | 1 |
| Maurel, S | 1 |
| De Vry, J | 1 |
| Schreiber, R | 1 |
| Knoke, DM | 2 |
| Pollock, BG | 1 |
| Mantere, T | 1 |
| Hall, H | 1 |
| Särkioja, T | 1 |
| Räsänen, P | 1 |
| Bergström, K | 1 |
| Callaway, J | 1 |
| Poulos, CX | 1 |
| Moore, N | 1 |
| Libert, C | 1 |
| Sellers, EM | 5 |
| Kadlec, KE | 1 |
| Kaplan, HL | 1 |
| Lawrin, MO | 1 |
| Sullivan, JT | 1 |
| Woodley, DV | 1 |
| Kadlec, K | 1 |
| Sykora, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase Four Double-Blind Randomized Comparative Study on Thestudy on the Efficacy of Memantine Hydrochloride and Escitalopram for the Treatment of Co-Morbid Depression and Alcoholism[NCT00368862] | Phase 4 | 80 participants | Interventional | 2005-12-31 | Completed | ||
| Sequenced Treatment Alternatives to Relieve Depression[NCT00021528] | Phase 4 | 4,000 participants | Interventional | 2001-07-31 | Completed | ||
| Predicting Alcoholics' Treatment Responses to an SSRI[NCT00249405] | Phase 2 | 200 participants (Anticipated) | Interventional | 2005-02-28 | Completed | ||
| A Double-Blind, Placebo-Controlled Study of Acamprosate Added to Escitalopram and Behavioral Treatment in Major Depressive Disorder (MDD) With Comorbid Alcohol Abuse/Dependence[NCT00452543] | Phase 4 | 23 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence[NCT01549652] | 133 participants (Actual) | Interventional | 2011-04-30 | Completed | |||
| Study to Determine Steady-state Level of Citalopram Pharmacokinetic Parameters in Patients With Short Bowel Syndrome[NCT00876226] | 0 participants (Actual) | Interventional | 2010-05-01 | Withdrawn | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Scores on the HAM-D-17 typically fall into the following ranges: a) Not depressed: 0-7; b) Mildly depressed: 7-15; c) Moderately depressed: 15-25; d) Severely depressed: over 25. A decrease of 50% or more in the Hamilton-D score is considered to be a positive response to treatment, while a score of 7 or less is considered typical of remission. We measure the change in total score from Baseline to Week 12 or week of early termination visit. (NCT00452543)
Timeframe: From baseline visit to Week 12 (or early discontinuation visit)
| Intervention | Scores on a scale (Mean) |
|---|---|
| Escitalopram Plus Acamprosate | -5.6 |
| Escitalopram Plus Placebo | -7.8 |
The TLFB assesses recent drinking behavior. On the TLFB, clients retrospectively estimate their daily alcohol consumption in standard drinks over a time period ranging from 7 days to 24 months prior to the interview, and thus the measure provides quantitative estimates of alcohol use. One standard drink on the TLFB was defined as: 12 oz beer (5% alcohol by volume), 5 oz of wine (10-12% abv), 3 oz of fortified wine (16-18% abv), or 1-1.2 oz of hard liquor (86-100 proof; 43-50% abv). We measure the change from Baseline to Week 12 or week of early termination visit. (NCT00452543)
Timeframe: From Baseline visit to Week 12 (or early discontinuation visit)
| Intervention | Drinking days (Mean) |
|---|---|
| Escitalopram Plus Acamprosate | 61 |
| Escitalopram Plus Placebo | 61 |
Total Drinks Consumed per Drinking Day on the Time Line Follow Back. We measure the change from Baseline to Week 12 or week of early termination visit. (NCT00452543)
Timeframe: From Baseline visit to Week 12 (or early discontinuation visit)
| Intervention | Drinks consumed per drinking day (Mean) |
|---|---|
| Escitalopram Plus Acamprosate | 4 |
| Escitalopram Plus Placebo | 4 |
Total Drinks Consumed per Week on the Time Line Follow Back. We measure the change from Baseline to Week 12 or week of early termination visit. (NCT00452543)
Timeframe: From Baseline visit to Week 12 (or early discontinuation visit)
| Intervention | Drinks consumed per week (Mean) |
|---|---|
| Escitalopram Plus Acamprosate | 15 |
| Escitalopram Plus Placebo | 15 |
The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -0.44 |
The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -2.68 |
The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken prior to receiving ondansetron or placebo, at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) |
|---|---|
| Prevention of Opioid Withdrawal | -2.59 |
The Beck Depression Inventory (a 21-item self-report multiple-choice inventory) yields a single summed score between 0 and 63; higher scores indicate more severe depression. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in BDIS (Ondansetron) | Change in BDIS (Placebo) | |
| Prevention of Physical Dependence | -0.6 | 0.2 |
"Originally developed by Handelsman, the Objective Opioid Withdrawal Scale (OOWS) score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The minimum score of 0 means the patient is not showing any signs of opioid withdrawal. The maximum score of 13 signifies all signs of opioid withdrawal to the largest extent possible.~Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If deemed necessary by the clinician, participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported." (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in OOWS (Ondansetron) | Change in OOWS (Placebo) | |
| Prevention of Opioid Withdrawal | 3.6 | 3.6 |
"Originally developed by Handelsman, the OOWS score is a well-characterized measure of opioid withdrawal in humans, calculated as the sum of a 13-item physician assessment documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. The maximum score is 13 and suggests the patient is showing all signs of opioid withdrawal to the largest extent possible. The minimum score of 0 suggests the patient is not showing any signs of opioid withdrawal.~Immediately prior to ondansetron or placebo administration a baseline OOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an OOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an OOWS score was taken. Change from the baseline OOWS score to the score assessed following the last naloxone dose is reported." (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in OOWS (Ondansetron) | Change in OOWS (Placebo) | |
| Prevention of Physical Dependence | 4.5 | 4.2 |
The VAS is a 0 to 100 millimeter scale where 0 corresponds to no pain and 100 to extreme pain, used by participants to indicated their level of pain over the last two weeks. Change is from baseline score for average level of pain (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in VAS Score (Ondansetron) | Change in VAS Score (Placebo) | |
| Prevention of Physical Dependence | -2.9 | -2.8 |
The Roland-Morris Disability Index is a 24-question instrument used to assess level of disability from lower back pain. Scores range from 0-24 with lower scores corresponding to fewer symptoms. Change is from baseline score (taken at the beginning of the first study visit, prior to beginning of titration into morphine) to the score taken after taking morphine for 30 days (score taken at the beginning of second study visit). (NCT01549652)
Timeframe: 2 study days 1 month apart (at the start of each study visit)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in RMDI (Ondansetron) | Change in RMDI (Placebo) | |
| Prevention of Physical Dependence | -4.6 | -2.0 |
The Subjective Opioid Withdrawal Score (SOWS) score is calculated as the sum of 16 subjective patient-reported symptom scores rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in SOWS (Ondansetron) | Change in SOWS (Placebo) | |
| Prevention of Opioid Withdrawal | 12.5 | 12.2 |
The SOWS score is composed of 16 subjective symptoms rated on a scale of 0 to 4 (0=not at all, 4=extremely) based on what subjects were experiencing at the time of testing. A maximum score of 64 would suggest the patient is experiencing the symptoms of withdrawal to the maximum extent possible while the lowest score of 0 would suggest the patient is not experiencing any of the symptoms of withdrawal. Immediately prior to ondansetron or placebo administration a baseline SOWS score was taken. 30 minutes later participants received naloxone, then 15 minutes later an SOWS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an SOWS score was taken. Change from the baseline SOWS score to the score assessed following the last naloxone dose is reported (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in SOWS (Ondansetron) | Change in SOWS (Placebo) | |
| Prevention of Physical Dependence | 16.4 | 12.0 |
Profile of Mood States (POMS) is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in POMS Score (Ondansetron) | Change in POMS Score (Placebo) | |
| Prevention of Opioid Withdrawal | 29.3 | 28.3 |
(Profile of Mood States) POMS is a 65-question survey of how participants have been feeling over the past week, assessing tension, depression, anger, fatigue, confusion and vigor. Each question is on a 5-point scale: 0 (not at all) to 4 (extremely). Overall score range: 0 to 200 (lower scores corresponding to fewer symptoms), calculated by adding total scores for tension, depression, anger, fatigue and confusing, and subtracting that total score from the total score for vigor. Immediately prior to ondansetron or placebo administration a baseline POMS score was taken. 30 minutes later participants received naloxone, then 15 minutes later a POMS score was taken. If necessary (as deemed by the clinician), participants may have received a second naloxone dose (25 minutes following 1st naloxone dose), then 15 minutes later an POMS score was taken. Change from the baseline POMS score to the score assessed following the last naloxone dose is reported. (NCT01549652)
Timeframe: Baseline; 15 minutes following last naloxone dose
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Change in POMS (Ondansetron) | Change in POMS (Placebo) | |
| Prevention of Physical Dependence | 36.1 | 29.2 |
5 reviews available for citalopram and Alcohol Abuse
| Article | Year |
|---|---|
Clinical pharmacology of serotonin-altering medications for decreasing alcohol consumption.
Topics: Alcohol Drinking; Alcoholism; Animals; Citalopram; Double-Blind Method; Humans; Randomized Controlle | 1993 |
Citalopram: a comprehensive review.
Topics: Alcoholism; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Clinical Trials | 2001 |
The role of selective serotonin reuptake inhibitors in reducing alcohol consumption.
Topics: Alcohol Drinking; Alcoholism; Animals; Behavior, Addictive; Behavior, Animal; Citalopram; Clinical T | 2001 |
Serotonin uptake inhibitors attenuate ethanol intake in problem drinkers.
Topics: Alcohol Drinking; Alcoholism; Brain; Citalopram; Clinical Trials as Topic; Humans; Receptors, Seroto | 1989 |
Modulation of ethanol intake by serotonin uptake inhibitors.
Topics: Acetaldehyde; Alcohol Drinking; Alcoholism; Animals; Brain; Citalopram; Disulfiram; Dopamine; Humans | 1986 |
26 trials available for citalopram and Alcohol Abuse
| Article | Year |
|---|---|
[Fluvoxamine in the treatment of depressive disorders in alcohol dependence: results of randomized open-label comparative study].
Topics: Alcoholism; Citalopram; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective | 2021 |
Sex differences in the ACTH and cortisol response to pharmacological probes are stressor-specific and occur regardless of alcohol dependence history.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Adult; Alcoholism; Citalopram; Corticotropin-Releasing | 2018 |
Effects of Citalopram on Cue-Induced Alcohol Craving and Thalamic D2/3 Dopamine Receptor Availability.
Topics: Administration, Intravenous; Adult; Alcoholism; Benzamides; Citalopram; Corpus Striatum; Craving; Cu | 2019 |
Depression outcome in alcohol dependent patients: an evaluation of the role of independent and substance-induced depression and other predictors.
Topics: Adolescent; Adult; Aged; Alcoholism; Citalopram; Depressive Disorder, Major; Drug Therapy, Combinati | 2015 |
A randomized trial of combined citalopram and naltrexone for nonabstinent outpatients with co-occurring alcohol dependence and major depression.
Topics: Adult; Affect; Alcoholism; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Diagnostic | 2015 |
Poorer Drinking Outcomes with Citalopram Treatment for Alcohol Dependence: A Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Adult; Aged; Alcoholism; Citalopram; Depression; Double-Blind Method; Female; Follow-Up Studies; Hum | 2015 |
Personality Predictors of Drinking Outcomes in Depressed Alcohol-Dependent Patients.
Topics: Adult; Alcoholism; Character; Citalopram; Depression; Drug Therapy, Combination; Female; Humans; Mal | 2016 |
Treatment of alcohol dependence in patients with co-morbid major depressive disorder--predictors for the outcomes with memantine and escitalopram medication.
Topics: Adult; Aged; Alcoholism; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, | 2008 |
Combining motivational interviewing with compliance enhancement therapy (MI-CET): development and preliminary evaluation of a new, manual-guided psychosocial adjunct to alcohol-dependence pharmacotherapy.
Topics: Adult; Aged; Alcohol Deterrents; Alcoholism; Behavior Therapy; Brief Psychiatric Rating Scale; Cital | 2010 |
A randomized, controlled, pilot study of acamprosate added to escitalopram in adults with major depressive disorder and alcohol use disorder.
Topics: Acamprosate; Adult; Alcoholism; Citalopram; Depressive Disorder, Major; Diagnosis, Dual (Psychiatry) | 2012 |
Adjunctive aripiprazole therapy with escitalopram in patients with co-morbid major depressive disorder and alcohol dependence: clinical and neuroimaging evidence.
Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Antipsychotic Agents; Aripiprazole; Citalop | 2013 |
Escitalopram/reboxetine combination in depressed patients with substance use disorder.
Topics: Adult; Alcoholism; Antidepressive Agents; Bipolar Disorder; Citalopram; Depressive Disorder, Major; | 2005 |
Citalopram neuropharmacological challenge in alcohol-dependent patients and controls: pharmacogenetic, endocrine and psychobehavioral results.
Topics: Adrenocorticotropic Hormone; Adult; Alcoholism; Alleles; Antidepressive Agents; Anxiety; Behavior; C | 2008 |
Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence.
Topics: Adult; Aged; Alcoholism; Ambulatory Care Facilities; Citalopram; Comorbidity; Depressive Disorder, M | 2008 |
An open randomized study of the treatment of escitalopram alone and combined with gamma-hydroxybutyric acid and naltrexone in alcoholic patients.
Topics: Adult; Alcoholism; Citalopram; Drug Therapy, Combination; Female; Humans; Hydroxybutyrates; Male; Mi | 2008 |
Effect of citalopram on alcohol intake in heavy drinkers.
Topics: Adult; Alcohol Drinking; Alcoholism; Citalopram; Cross-Over Studies; Dose-Response Relationship, Dru | 1994 |
Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems.
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Behavior Therapy; Citalopram; Combined Modality Therapy; | 1995 |
Neuroendocrine evidence for reduced serotonergic neurotransmission during heavy drinking.
Topics: Adult; Alcoholic Intoxication; Alcoholism; Body Temperature Regulation; Citalopram; Cross-Over Studi | 1994 |
Citalopram in the treatment of alcoholism: a double-blind placebo-controlled study.
Topics: Adult; Alcoholism; Antidepressive Agents; Citalopram; Double-Blind Method; Finland; Humans; Male; Mi | 1996 |
Using fuzzy logic to predict response to citalopram in alcohol dependence.
Topics: Alcoholism; Citalopram; Cross-Over Studies; Double-Blind Method; Female; Fuzzy Logic; Humans; Male; | 1997 |
Variations in response to citalopram in men and women with alcohol dependence.
Topics: Adult; Alcoholism; Anxiety; Citalopram; Depression; Female; Humans; Male; Prospective Studies; Selec | 2000 |
Mental well-being in subjects with long-term excessive alcohol consumption: an experimental study.
Topics: Adult; Affect; Alcohol Drinking; Alcoholism; Citalopram; Humans; Male; Mental Health; Middle Aged; M | 2002 |
Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkers.
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Citalopram; Compliance; Double-Blind Method; Female; Huma | 1992 |
Serotonin uptake inhibitors attenuate ethanol intake in problem drinkers.
Topics: Alcohol Drinking; Alcoholism; Brain; Citalopram; Clinical Trials as Topic; Humans; Receptors, Seroto | 1989 |
Limitations in the measurement of urine ethanol in clinical trials to monitor ethanol consumption.
Topics: Adult; Alcohol Drinking; Alcoholism; Citalopram; Clinical Trials as Topic; Double-Blind Method; Etha | 1988 |
The serotonin uptake inhibitor citalopram attenuates ethanol intake.
Topics: Adult; Alcohol Drinking; Alcoholism; Citalopram; Double-Blind Method; Drug Evaluation; Humans; Male; | 1987 |
24 other studies available for citalopram and Alcohol Abuse
| Article | Year |
|---|---|
Drug trials in psychiatry: methodological issues.
Topics: Alcoholism; Chlordiazepoxide; Citalopram; Depressive Disorder; Diabetes Mellitus; Female; Humans; Hy | 2014 |
Lower [3H]Citalopram binding in brain areas related to social cognition in alcoholics.
Topics: Adult; Alcoholism; Autoradiography; Brain; Case-Control Studies; Citalopram; Dorsal Raphe Nucleus; F | 2015 |
Family history of depression and therapeutic outcome: findings from STAR*D.
Topics: Adult; Age Factors; Alcoholism; Antidepressive Agents; Anxiety Disorders; Citalopram; Comorbidity; C | 2009 |
Age at onset of first depressive episode as a predictor for escitalopram treatment of major depression comorbid with alcohol dependence.
Topics: Adult; Age of Onset; Aged; Alcoholism; Antidepressive Agents; Citalopram; Comorbidity; Depressive Di | 2009 |
Attenuation of apparent new-onset ocular tics with successful treatment of PTSD.
Topics: Alcoholism; Antidepressive Agents, Second-Generation; Citalopram; Combined Modality Therapy; Humans; | 2009 |
Multifactorial QT interval prolongation.
Topics: Alcoholism; Amiodarone; Antipsychotic Agents; Arrhythmias, Cardiac; Biomarkers; Citalopram; Cyclohex | 2010 |
Serotonin transporter polymorphism as a predictor for escitalopram treatment of major depressive disorder comorbid with alcohol dependence.
Topics: Adult; Alcoholism; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; | 2011 |
Neuroendocrine assessment of serotonergic, dopaminergic, and noradrenergic functions in alcohol-dependent individuals.
Topics: Adult; Alcoholism; Biomarkers; Case-Control Studies; Citalopram; Clonidine; Dopamine; Female; Human | 2012 |
[Antidepressants in the treatment of alcoholism].
Topics: Alcoholism; Antidepressive Agents; Citalopram; Comorbidity; Depression; Humans | 2012 |
Childhood maltreatment affects the serotonergic system in male alcohol-dependent individuals.
Topics: Adult; Adult Survivors of Child Abuse; Alcoholism; Citalopram; Humans; Male; Middle Aged; Prolactin; | 2013 |
Hormone responses to citalopram in abstinent alcohol dependent subjects.
Topics: Adrenocorticotropic Hormone; Adult; Alcoholism; Citalopram; Hormones; Humans; Hydrocortisone; Male; | 2002 |
Delusional wife: a case of diagnostic ambiguity and treatment challenge.
Topics: Adult; Alcoholism; Antipsychotic Agents; Benzodiazepines; Citalopram; Delusions; Depressive Disorder | 2005 |
Lower serotonin transporter binding in caudate in alcoholics.
Topics: Alcoholism; Autoradiography; Caudate Nucleus; Citalopram; Data Interpretation, Statistical; Female; | 2006 |
Increased deep sleep in a medication-free, detoxified female offender with schizophrenia, alcoholism and a history of attempted homicide: effect of concomitant administration of quetiapine and citalopram.
Topics: Adult; Aggression; Alcoholism; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Antis | 2006 |
Nucleus accumbens serotonin transporters in alcoholics measured by whole-hemisphere autoradiography.
Topics: Adult; Aged; Alcoholism; Autoradiography; Binding Sites; Case-Control Studies; Citalopram; Female; F | 2006 |
Amygdala serotonin transporters in alcoholics measured by whole hemisphere autoradiography.
Topics: Alcoholism; Amygdala; Autoradiography; Citalopram; Female; Humans; Male; Middle Aged; Serotonin Plas | 2007 |
Effects of various serotonergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference.
Topics: Alcohol Drinking; Alcoholism; Animals; Buspirone; Chlordiazepoxide; Citalopram; Dose-Response Relati | 1993 |
Effects of chronic ethanol consumption and aging on 5-HT2A receptors and 5-HT reuptake sites.
Topics: Age Factors; Aged; Alcoholism; Animals; Autoradiography; Brain; Brain Mapping; Cellular Senescence; | 1997 |
Citalopram as an inhibitor of voluntary ethanol intake in the male rat.
Topics: Alcoholism; Animals; Body Weight; Citalopram; Drinking; Drug Tolerance; Ethanol; Male; Rats; Rats, S | 1998 |
Comparison of the effects of the selective serotonin-reuptake inhibitors fluoxetine, paroxetine, citalopram and fluvoxamine in alcohol-preferring cAA rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Citalopram; Disease Models, Animal; Eating; Ethanol; Female; | 1999 |
Serotonin transporter distribution and density in the cerebral cortex of alcoholic and nonalcoholic comparison subjects: a whole-hemisphere autoradiography study.
Topics: Adolescent; Adult; Affect; Aged; Alcoholism; Autoradiography; Carrier Proteins; Cerebral Cortex; Cit | 2002 |
Acamprosate, citalopram, and alcoholism.
Topics: Acamprosate; Alcoholism; Citalopram; Clinical Trials as Topic; gamma-Glutamyltransferase; Humans; Ta | 1991 |
Acamprosate, citalopram, and alcoholism.
Topics: Acamprosate; Alcoholism; Citalopram; Humans; Patient Dropouts; Taurine | 1991 |
Therapeutic use of serotonergic drugs in alcohol abuse.
Topics: Alcohol Drinking; Alcoholism; Animals; Biomechanical Phenomena; Citalopram; Propylamines; Rats; Sero | 1986 |